Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Carcinoma, Medullary × anlotinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 3 Stomach Neoplasms 1 Sarcoma 1 Neoplasms 1 Esophageal Squamous Cell Carcinoma 1 Differentiated Thyroid Cancer 1 Colorectal Neoplasms 1 Carcinoma, Medullary 1 Biliary Tract Neoplasms 1 Advanced Solid Tumor 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02586350 2019-05-21

Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2/3 Completed

Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡